Akari Therapeutics (AKTX) Expected to Announce Quarterly Earnings on Friday

Akari Therapeutics (NASDAQ:AKTX) is anticipated to announce its Q3 2025 results before the market opens on Friday, December 5th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earning report page for the latest details on the call scheduled for Thursday, November 13, 2025 at 12:00 AM ET.

Akari Therapeutics Price Performance

Shares of Akari Therapeutics stock opened at $0.34 on Thursday. Akari Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.73. The stock has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $0.94.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AKTX. HC Wainwright reissued a “buy” rating and issued a $1.60 price target on shares of Akari Therapeutics in a research report on Tuesday, September 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Akari Therapeutics has a consensus rating of “Hold” and an average price target of $3.30.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.